Clene Inc CLNN
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-08-27 |
| Shares Out. | 12,780,000 |
| Website | clene.com/ ↗ |
| Phone | 18003464646 |
| Employees | 79 |
| Revenue | $15,000 |
| Gross Profit | $15,000 |
| Net Income | -$8.1M |
| Free Cash Flow | -$18.1M |
| Total Assets | $21.7M |
| Total Liabilities | $40.5M |
| Equity | -$18.8M |
About Clene Inc
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
Clene Inc is a publicly traded company under the ticker symbol CLNN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-07-01)